Hair loss affects more than just appearance; it can significantly impact confidence and overall wellbeing. Clinically proven, non-invasive treatments that guarantee results have been the dream of every individual struggling with the effects of hair loss. Pharma Hermetic has been turning this dream into reality with its peptide-based treatments that address the root causes of hair loss. With two decades of expertise in biotechnology and cosmeceuticals, the Barcelona-based company offers clinically backed products that deliver long-term benefits without the need for invasive procedures. “We started Pharma Hermetic because we saw too many people losing confidence in the available treatments for hair loss,” says Adrián Quiroga, CEO. “Our goal is to give them a solution they could trust, something that truly works without compromising their well-being.” Pharma Hermetic’s solutions address hair loss at its root through treatments that block dihydrotestosterone activity and activate telomerase, a key factor in follicle health. These formulations are primarily recommended by dermatologists and trichologists. Its flagship product, hair recovery program SP55 vials, is a topical formulation that combines 11 clinically and dermatologically tested bioactive peptides, plant extracts and vitamins. With high concentration of active ingredients, the product has demonstrated lasting efficacy. It also actively addresses androgenetic alopecia, the most common form of hair loss in men, by targeting DHT, the hormone largely responsible for male pattern baldness. Its peptide formulations are designed to block the formation of DHT and inhibit 5-alpha reductase while promoting telomerase activity to encourage cell regeneration. A simplified maintenance routine is recommended for patients with this condition, which includes using one vial per month after achieving visible results. This approach combines scientific innovation with convenience, making it well-suited for both men and women seeking long-term, low-effort results. As a part of its comprehensive hair recovery program, the company has developed two comprehensive solutions—Silver Kit and Blue Line. The Silver Kit combines Pharma Hermetic’s three core products into a single, easy-to-use package designed for a two-month application period, supported by a detailed calendar that guides users through daily applications. The Blue Line can be used individually or with other therapies. Together, these offerings have contributed to the widespread adoption of Pharma Hermetic’s products in over 40 countries. .

PHARMExcel is not a typical contract research organisation (CRO). It has carved out a distinctive niche—supporting academic institutions, spin-outs and public health bodies in translating groundbreaking research into real-world patient outcomes with tailored clinical trial support. The idea of stepping away from the standard CRO model, which is often driven by commercial returns, came from founder and CEO Yvanne Enever. During her time working with the clinical research team at University College London, she witnessed firsthand the lack of operational infrastructure researchers face when trying to move innovation forward. Earlier in her career, as a nurse and senior transplant practitioner within the UK National Health Service (NHS), she had already seen the other side of that equation - patients in urgent need of novel therapies. That dual perspective became the foundation for PHARMExcel. “For us, it’s never just about ticking boxes or delivering data,” Enever says. “It’s about knowing that what we do could help bring a life-changing treatment to someone who really needs it. That’s the bigger picture we’re always working toward, helping innovation reach the people it’s meant to help.” That conviction is evident in how PHARMExcel operates. Its in-house experts lead every protocol development effort with a deep understanding of the therapeutic area and the context in which care is delivered. Rather than applying a rigid framework, PHARMExcel shapes each trial around clinical realities—what’s feasible, relevant and meaningful in practice. The deep expertise in international regulatory guidelines equips clients to advance their innovations with confidence and compliance. What truly sets the company apart is its early and intentional inclusion of the patient voice. Involving patients’ voices from the outset, protocols are not only more aligned with clinical objectives but with the lived experiences of those participating. This patient-centric design approach improves engagement, supports better recruitment and retention and raises the chances of a trial reaching approval. This proved invaluable when PHARMExcel partnered with an academic spin-out on the cusp of a breakthrough—gene therapy for a rare paediatric disease. While the science was promising, translating it into a viable clinical trial posed significant challenges - navigating complex regulatory frameworks, ensuring patient safety and building a protocol that could withstand both scientific and ethical scrutiny..